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756Background: Etanercept is approved for the treatment of chronic moderate to severe plaque psoriasis in
adults.Objective: We sought to evaluate the long-term safety of etanercept in a real-world clinical setting.
Assessment of etanercept efficacy was a secondary objective.Methods: OBSERVE-5 is a 5-year observational safety registry initiated in May 2006 at multiple sites in
the United States and Canada. Data collection includes the number of serious adverse events,
serious infectious events, and prespecified events of medical interest. Efficacy data include
body surface area assessments, physician and patient global assessments of psoriasis, and the
Dermatology Life Quality Index. This interim analysis presents data from the first 3 years of the follow-
up period.Results: A total of 2511 patients were enrolled. Of 1890 patients continuing in the registry after 3 years,
113 were inactive for 1 to 2 years, and 115 were inactive for longer than 2 years. The 3-year incidence
proportions of serious adverse events and serious infectious events based on Kaplan-Meier methodology
were 0.14 and 0.04, respectively. The observed numbers of patients experiencing lymphoma, serious
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administrative health claims database.Limitations: The registry lacks a control group, and the study is too small to measure the frequency of rare
events.Conclusion: Etanercept demonstrated good tolerability in patients with plaque psoriasis in the clinical
setting in this interim analysis. No new or unexpected safety concerns were observed. ( J Am Acad
Dermatol 2013;68:756-64.)
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d Previous data from randomized,
controlled clinical trials have
demonstrated that etanercept is safe and
effective in patients with moderate to
severe plaque psoriasis.
d This postmarketing safety registry
provides data on the first 3 years of a
5-year observational study on real-world
use of etanercept in this patient
population.
d No new or unexpected safety signals
were observed with the use of
etanercept in this interim observational
analysis.Psoriasis is a chronic, po-
tentially debilitating, inflam-
matory skin disease that
affects approximately 2% to
3% of individuals in the
United States.1,2 Health-
related quality of life is often
reduced in patients with active
psoriasis, and approximately
one quarter of patients with
psoriasis report that thedisease
presents a large problem in
their daily lives.2
Psoriasis treatments in-
clude topical therapy,
phototherapy, nonbiologic
systemic agents, and biologic
therapy.3 Etanercept is a fully
human, soluble tumor necro-
sis factor (TNF) receptor fu-
sion protein approved in the United States for
treating adult patients with chronic moderate to
severe plaque psoriasis who are candidates for
systemic therapy or phototherapy.4 Etanercept has
demonstrated clinical efficacy and good tolerability
in short- and long-term (up to 2.5 years) clinical trials
in patients with moderate to severe plaque
psoriasis.5-11
Observational registries are useful in that they
accumulate long-termdata fromamoreheterogeneous
real-world cohort of patients with respect to baseline
demographics, disease severity, and comorbid condi-
tions, as compared with clinical trials. Such registries
also facilitate detection of long-term effects and other
risks thatmayaffect therisk-benefitprofile fora specific
group of patients. OBSERVE-5 is a prospective 5-year
observational safety registry designed to gather data on
the long-term safety of etanercept in a large population
of patients with plaque psoriasis. This report presents
interim 3-year data for OBSERVE-5.
METHODS
Study design
This postmarketing phase IV cohort study (clinical
trial registry NCT00322439) was initiated at 375 sites(338 in the United States,
37 in Canada) in May 2006
and is continuing at 286 sites
(257 in the United States,
29 in Canada). The planned
duration of follow-up is
5 years. This prespecified in-
terim report includes 3-year
data available from study
start through January 20,
2011. The primary objective
of this registry was to assess
the long-term safety of eta-
nercept in patients with
plaque psoriasis, as deter-
mined by evaluating the
incidence proportions of
serious adverse events (in-
cluding serious infectious
events). A key secondary ob-jective was to assess etanercept safety by evaluating
incidence proportions of prespecified events of
medical interest.
Patients with plaque psoriasis for whom etaner-
cept was indicated per prescribing information were
eligible for inclusion in the registry. Patients were
excluded if they had been treatedwith any other TNF
inhibitor, had been treated with etanercept before
April 2004 in the United States or before December
2005 in Canada (approval dates for etanercept for the
psoriasis indication), had participated in a previous
etanercept clinical trial, or had contraindications to
etanercept treatment according to prescribing infor-
mation (ie, sepsis).
The etanercept dose and dosing regimen was
determined by the study investigator. During the
follow-up period, patients may have discontinued
etanercept treatment, switched to another antipsori-
atic treatment, used etanercept in combination with
other antipsoriatic treatments, or discontinued all
antipsoriatic treatments. Patients were evaluated at
least twice yearly (at approximately 6-month
intervals).
Serious adverse events (including serious infec-
tious events) were assessed as the primary study
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BSA: body surface area
CI: confidence interval
NMSC: nonmelanoma skin cancer
TNF: tumor necrosis factorobjective. A serious adverse event was defined as
one that suggests a significant hazard or adverse
event. This included, but was not limited to, any
event that was fatal, was life threatening, required
overnight inpatient hospitalization or prolongation
of hospitalization, was a persistent or significant
disability/incapacity, was a congenital anomaly/
birth defect, or other significant medical hazard.
Prespecified events of medical interest (key second-
ary study objective) were defined as serious and
nonserious adverse events of malignancies, tuber-
culosis, opportunistic infections treated with
intravenous therapy, histoplasmosis or coccidioido-
mycosis treated with oral antibiotics, central nervous
system demyelinating disorders, lupus, coronary
artery disease, and worsening psoriasis (defined by
change in psoriasis morphology and withdrawal of
therapy due to worsening of psoriasis). Such events
were coded according to the Medical Dictionary for
Regulatory Activities preferred terms. Also included
were any adverse events or laboratory abnormalities
that, in the investigator’s opinion, were events of
medical significance.
Retention efforts included encouragement of sites
to conduct telephone reminders of approaching
visits, distribution of retention packages containing
visit reminder cards to the investigator sites, and
reimbursement of sites for efforts to remind patients.
In the event of patient relocation, patient transfer to
another investigative site was permitted. Telephone
visits, where adverse event information was ob-
tained from patients via telephone, even in the
absence of a direct physical examination, were
permitted. The sponsor company did not provide
study drug to the participants.
Incidence proportions for serious adverse
events, serious infectious events, and events of
medical interest were calculated using Kaplan-
Meier methodology to adjust for varying exposure
as a result of dropouts. The incidence proportions
represent the probability that an event occurs
within a given time period. Because the study
does not include an internal comparison group,
rates of specific events of interest (malignancies,
lymphoma, nonmelanoma skin cancer [NMSC], in-
fections requiring hospitalization) were assessed
against background rates from an external
database.Outcomes data were also collected to assess
treatment efficacy, impact on health-related quality
of life, and health care resource use. Key outcomes
measures presented here are the change in body
surface area (BSA) affected by psoriasis and the
patient and physician global assessments (using a
6-point Likert scale, 0-5; 0 or 1 represents clear or
almost-clear status in the physician global assess-
ment), with higher scores indicating more severe
psoriasis. For these analyses, no imputation was
performed for missing data. The study is being
conducted in compliance with the Declaration of
Helsinki. The study protocol and informed consent
forms were approved by all institutional review
boards, and all patients provided written consent
before starting study-specific procedures.12
Data analysis
The primary analysis set was all patients who
received at least 1 dose of etanercept. For the
primary analysis, incidence proportions of serious
adverse events and serious infections were calcu-
lated using Kaplan-Meier methodology. Follow-up
for each patient began on the date of the first dose of
etanercept during the study and time at risk contin-
ued until the occurrence of the first event or until the
end of the study.
In addition to the Kaplan-Meier analyses of inci-
dence proportions, incidence rates based on patient-
years of exposure and patient-years of observation
were calculated. This methodology was used to align
to that used in the calculation of expected incidence
rates derived from the external database. This anal-
ysis provided context for the observational safety
results obtained from the study. For calculations of
incidence rates per patient-years of exposure, all
events that occurred during etanercept exposure
were included. Exposure was calculated as the
duration of time on etanercept, including a 30-day
risk window after each dosing period. For calcula-
tions of incidence rates per patient-years of obser-
vation, all events that occurred during the registry
were included and observation was calculated as the
duration of time on the study (including breaks in
etanercept use, if any). Follow-up time was trun-
cated at the first occurrence of the event for each
subject or at the end of the study. All events were
included in the analysis. For those events where no
date was available (n = 10), the unknown start dates
for the event were estimated for each subject as the
baseline registry date plus one half of the total
observed duration that the subject was in the study
(ie, the middle of the exposure period).
For the external comparator analysis, the inci-
dence rates of the following events were estimated
Table I. Patient attributes
Prior
etanercept*
Etanercept
naivey Total
Enrolled, n 664 1847 2511
Received $ 1
etanercept dose, n
664 1847 2511
Patients continuing in
study, n (%)
509 (76.7) 1381 (74.8) 1890 (75.3)
Last visit within 1 y 456 (68.7) 1206 (65.3) 1662 (66.2)
No visits for 1-2 y 21 (3.2) 92 (5.0) 113 (4.5)
No visits for[2 y 32 (4.8) 83 (4.5) 115 (4.6)
Patients discontinued
from study, n (%)
155 (23.3) 466 (25.2) 621 (24.7)
Consent withdrawn 52 (7.8) 250 (13.5) 302 (12.0)
Administrative
decision
24 (3.6) 57 (3.1) 81 (3.2)
Ineligibility
determined
56 (8.4) 11 (0.6) 67 (2.7)
Lost to follow-up 4 (0.6) 57 (3.1) 61 (2.4)
Disease progression 3 (0.5) 32 (1.7) 35 (1.4)
Death 9 (1.4) 21 (1.1) 30 (1.2)
Adverse event
(other than death)
4 (0.6) 14 (0.8) 18 (0.7)
Noncompliance 2 (0.3) 12 (0.6) 14 (0.6)
Protocol deviation 1 (0.2) 6 (0.3) 7 (0.3)
Pregnancy 0 (0) 1 (0.1) 1 (\0.1)
Other 0 (0) 5 (0.3) 5 (0.2)
*Includes patients with etanercept exposure before registry.
yIncludes patients with no etanercept exposure before registry
who initiated etanercept for first time at baseline.
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claims database (Market-Scan, Truven Health
Analytics Inc, Ann Arbor, MI): malignancies (all
cancers combined including lymphoma, but exclud-
ing NMSC [basal cell carcinoma and squamous cell
carcinoma]), lymphoma, NMSC, and serious infec-
tions requiring hospitalization.13 A psoriasis cohort
was selected based on evidence of having more than
1 inpatient or more than 2 outpatient claims with the
International Classification of Diseases, Ninth
Revision, Clinical Modification code for psoriasis
(696.1) and the specific treatment cohorts were
selected based on first medication prescribed.
Among 48,136 patients with a diagnosis of psoriasis
in the database, 7.6% were prescribed nonbiologic
systemic therapies, 4.1% other TNF blocker thera-
pies, 10.7% etanercept, and 8.0% were undergoing
phototherapy.14 The primary comparator group was
a cohort of patients with psoriasis prescribed meth-
otrexate or cyclosporine (nonbiologic systemic ther-
apies). They had a mean (SD) of 2.1 (1.0) years of
enrollment and a mean (SD) duration of therapy of
0.7 (0.8) years. This group was selected as the
comparator group because they were more likely
to have psoriasis disease severity that was compara-
ble with a group given etanercept.
Because of the longer latency of cancers, the
primary comparison for all cancers (excluding
NMSC), lymphoma, and NMSC was performed using
patient-years of observation. For hospitalized infec-
tions, which have a more acute effect, the primary
comparison was made using patient-years of
exposure. Incidence rates, which were age- and
sex-standardized to the OBSERVE-5 population, for
these 4 types of events were estimated for a psoriasis
population prescribed methotrexate or cyclosporine
(nonbiologic systemic therapies) based on the first
medication prescribed. A standardized incidence
ratio and 95% confidence intervals (CI) were calcu-
lated to compare the number of observed patients
experiencing events in the registry with the number
of expected patients from the comparator group in
the administrative health claims database.RESULTS
Of 2511 patients initially enrolled in the registry,
1890 (75%) were still participating at the time of this
interim analysis. Of these ongoing patients,
1662 (66.2%) patients had been evaluated in the
past year, 113 had not been evaluated for 1 to 2 years,
and 115 had not been evaluated for more than 2
years. The most common reason for discontinuation
from the study was withdrawn consent; all of the
reasons given for discontinuation are listed in Table I.At 3 years, 272 (10.8%) patients were considered
discontinued without resumption of therapy.
The majority of patients were white and younger
than 65 years, with approximately equal numbers of
men and women enrolled (Table II). There were
664 patients with etanercept exposure before the
registry (ie, prior etanercept group) and 1847 pa-
tients with no etanercept exposure before the
registry who initiated etanercept for the first
time at baseline (ie, etanercept-naive group). The
mean 6 SD duration of psoriasis at screening was
18.4 6 12.9 years in the prior etanercept group and
14.7 6 12.5 years in the etanercept-naive group. In
the prior etanercept group, approximately 25% of
patients had baseline percentages of BSA affected
by psoriasis of less than 2%. In the etanercept-naive
population, approximately 25% of patients had
baseline percentages of BSA affected by psoriasis
of less than 10%. The most common comorbid
conditions at screening among all 2511 patients
were arterial hypertension (28.5%), hypercholester-
olemia/hyperlipidemia (18.7%), psoriatic arthritis
(18.5%), and type 1 or type 2 diabetes (10.5%).
The demographic characteristics of the patients
with previous exposure to etanercept (n = 664)
Table II. Patient demographics and clinical
characteristics
Prior
etanercept*
(n = 664)
Etanercept
naivey
(n = 1847)
Total
(n = 2511)
Sex, n (%)
Men 378 (56.9) 939 (50.8) 1317 (52.4)
Women 286 (43.1) 908 (49.2) 1194 (47.6)
Age, y
Mean 6 SD 48.5 6 12.6 45.6 6 13.9 46.3 6 13.6
Range 19-86 11-92 11-92
Age group, n (%)
\65 y 601 (90.5) 1697 (91.9) 2298 (91.5)
$ 65 y 63 (9.5) 150 (8.1) 213 (8.5)
Race, n (%)
White 546 (82.2) 1507 (81.6) 2053 (81.8)
Black 29 (4.4) 79 (4.3) 108 (4.3)
Hispanic
or Latino
35 (5.3) 129 (7.0) 164 (6.5)
Asian 31 (4.7) 85 (4.6) 116 (4.6)
Other 23 (3.5) 47 (2.5) 70 (2.8)
Highest level
of school
completed, n (%)
Grade 8 7 (1.1) 41 (2.2) 48 (1.9)
Grade 12 or GED 206 (31.0) 609 (33.0) 815 (32.5)
Technical school 26 (3.9) 61 (3.3) 87 (3.5)
Some college 138 (20.8) 401 (21.7) 539 (21.5)
College 204 (30.7) 544 (29.5) 748 (29.8)
Postgraduate 83 (12.5) 189 (10.2) 272 (10.8)
Unknown 0 (0.0) 2 (0.1) 2 (0.1)
Present employment
status, n (%)
Full time
($ 35 h/wk)
466 (70.2) 1216 (65.8) 1682 (67.0)
Part time
(\35 h/wk)
38 (5.7) 139 (7.5) 177 (7.0)
Temporarily
employed
1 (0.2) 3 (0.2) 4 (0.2)
Disabled 25 (3.8) 67 (3.6) 92 (3.7)
Retired 83 (12.5) 218 (11.8) 301 (12.0)
Unemployed 31 (4.7) 164 (8.9) 195 (7.8)
Other 20 (3.0) 40 (2.2) 60 (2.4)
Duration of
psoriasis, y
Mean 6 SD 18.4 6 12.9 14.7 6 12.5 15.7 6 12.7
Median 16.6 11.1 12.6
Range 0-69.7 0-78.6 0-78.6
Baseline body
surface area
affected by
psoriasis, %
Mean 6 SD 11.7 6 14.5 24.5 6 20.3 21.1 6 19.8
Median (IQR) 6.0 (2-15) 17.0 (10-34) 15.0 (8-30)
Range 0-96.0 0-100.0 0-100.0
GED, General equivalency diploma; IQR, interquartile range.
*Includes patients with etanercept exposure before registry.
yIncludes patients with no etanercept exposure before registry
who initiated etanercept for first time at baseline.
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(n = 1847) were similar.
During the follow-up period, mean6 SD duration
of etanercept exposure was 1.76 1.1 years and 1.66
1.1 years in the prior etanercept and etanercept-
naive groups, respectively. In total, 846 (33.7%)
patients were receiving etanercept at 3 years,
291 of whom had no gaps in treatment, and 1509
patients discontinued etanercept or changed doses
at least once. The median number of etanercept
discontinuations or dose changes per patient was 1.0
(range, 1-10). The most common reasons for initial
discontinuation of etanercept were other (n = 272),
alternative psoriasis therapy prescribed (n = 205),
nonserious adverse event (n = 180), subject request
(n = 164), insurance change (n = 149), and disease
progression (n = 138).
Safety
A total of 145 patients discontinued etanercept
because of 1 or more adverse events; the most
common of these events were cellulitis (n = 8),
pneumonia (n = 8), hypoesthesia (n = 6), paresthesia
(n = 5), dyspnea (n = 4), and worsening psoriasis
(n = 4). Thirty patients died during the follow-up
period, and these fatal adverse events are summa-
rized in Table III. Three of these deaths (idiopathic
pulmonary fibrosis, osteomyelitis and sepsis, and
cardiac failure) were judged by the investigator to be
related to etanercept. However, the relationship of
these deaths to etanercept was confounded by pre-
existing conditions in 2 of the 3 patients and by the
period of time not receiving etanercept in the third
patient. One of these patients was a 77-year-old man
with a history of acute bronchitis, chronic obstructive
pulmonary disease, and pulmonary fibrosis. He
developed interstitial pneumonia (idiopathic pulmo-
nary fibrosis) and was hospitalized on the same date
(September 5, 2010). Etanercept was discontinued
(date of first and last dose not specified). The patient
subsequently died of interstitial pneumonia on
October 7, 2010; the investigator thought there was
a reasonable possibility that this pneumonia was
related to etanercept. The other patient with con-
founding pre-existing conditions was a 64-year-old
man on dialysis with a history of insulin-dependent
diabetes mellitus, myocardial infarction, bypass
graft, angioplasty, foot amputation, diverticulosis,
and multiple back surgeries. Approximately 70 days
after initiation of etanercept treatment, he developed
pain and fever in an unspecified location, was
hospitalized 6 days later with sepsis and osteomye-
litis, underwent unspecified back surgery for the
sepsis, and died approximately 1 week later. The
investigator thought that the initial pain was
Table III. Fatal adverse events occurring during
follow-up period
Patients, n
Total No. of patients with fatal adverse events 30
Unknown cause of death 6
Myocardial infarction 4
Cardiac failure 2
Completed suicide 2
Pneumonia 2
Sepsis 2
Abdominal pain 1
Alcoholic pancreatitis 1
Asphyxia 1
Chronic obstructive pulmonary disease 1
Crushing injury of trunk 1
Drug toxicity 1
Generalized edema 1
Hepatic cirrhosis 1
Hepatic encephalopathy 1
Idiopathic pulmonary fibrosis 1
Large-cell carcinoma of respiratory tract 1
Lung cancer, metastatic 1
Lung neoplasm, malignant 1
Multiorgan failure 1
Myelodysplastic syndrome 1
Neoplasm, malignant 1
Bladder cancer 1
Osteomyelitis 1
Pancreatic carcinoma 1
Renal failure, chronic 1
Respiratory failure 1
Road traffic accident 1
Not all patients were receiving etanercept throughout follow-up
period. Six patients had[1 reported fatal events.
Table IV. Serious adverse events, serious infectious
events, serious infectious events requiring
hospitalization, and events of medical interest
occurring in 5 or more patients during follow-up
period
Patients, n
Patients enrolled, total 2511*
Serious adverse events, total 290
Cellulitis 17
Pneumonia 17
Myocardial infarction 13
Coronary artery disease 9
Dyspnea 8
Osteoarthritis 7
Angina pectoris 6
Atrial fibrillation 6
Cholecystitis 6
Diverticulitis 6
Intervertebral disk protrusion 6
Nephrolithiasis 6
Staphylococcal infection 6
Death 6
Chronic obstructive pulmonary disease 5
Dehydration 5
Pancreatitis 5
Serious infectious events, totaly 82
Cellulitis 17
Pneumonia 17
Diverticulitis 6
Staphylococcal infection 6
Serious infectious events requiring
hospitalization, totaly
61
Pneumonia 16
Cellulitis 15
Events of medical interest, total 459
Otherz 359
Malignancy 87
Coronary artery disease 33
Worsening psoriasis 7
Central nervous system demyelinating
disorders
6
*No. of patients who received at least 1 registry dose of
etanercept. Not all patients were receiving etanercept
throughout evaluation period.
ySerious infectious events are subset of serious adverse events,
and serious infectious events requiring hospitalization are subset
of serious infectious events.
zIncludes any event or laboratory abnormality that, in
investigator’s opinion, represents event of medical significance.
Events in this category reported in $ 5 patients included
sinusitis (n = 24); upper respiratory tract infection (n = 16);
pneumonia (n = 15); positive tuberculin test result (n = 14);
bronchitis (n = 13); hypertension (n = 12); cellulitis, diabetes
mellitus, paresthesia (n = 11 each); hypoesthesia, type 2 diabetes
mellitus (n = 9 each); psoriasis (n = 8); urinary tract infection
(n = 7); arthralgia, hepatic steatosis, nephrolithiasis (n = 6 each);
and cough, fatigue, gastroesophageal reflux disease, herpes
zoster, injection site erythema, rash (n = 5 each).
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osteomyelitis were possibly related to etanercept.
The third death occurred in a 72-year-old woman
with a history of osteoporosis, small-cell carcinoma
of the lung, and squamous cell carcinoma of the
labia, who had discontinued etanercept in October
2009, after 2 years and 4 months of treatment. She
subsequently discontinued all medications, became
comatose, and died in March 2010, with no cause of
death initially reported. The investigator judged
there was a reasonable possibility that her death
was related to etanercept. The cause of death was
later confirmed to have been heart failure.
A total of 290 patients had 1 or more serious
adverse events, including 82 patients with 1 or more
serious infectious events and 61 patients with 1 or
more serious infectious events requiring hospitaliza-
tion. Events occurring in 5 or more patients are listed
in Table IV. The Kaplan-Meier estimated 3-year
incidence proportion for serious adverse events
was 0.14 (0.13-0.16) (Table V). The incidence rate
Table V. Kaplan-Meier analysis and exposure-adjusted incidence of serious adverse events and serious
infectious events during follow-up period
No. of patients
with event
Incremental yearly
incidence proportion
(95% CI)
Cumulative
incidence proportion
(95% CI)
Serious adverse events
Kaplan-Meier method
Year 1 141 0.0605 (0.0508-0.0703) 0.0605 (0.0508-0.0703)
Year 2 98 0.0488 (0.0394-0.0583) 0.1094 (0.0962-0.1225)
Year 3 51 0.0318 (0.0231-0.0405) 0.1412 (0.1258-0.1565)
Incidence rate per 100 person-years of exposure
(95% CI)
213 5.18 (4.51-5.93)
Incidence per 100 person-years of observation
(95% CI)
290 5.58 (4.96-6.27)
Serious infectious events
Kaplan-Meier method
Year 1 44 0.0188 (0.0133-0.0243) 0.0188 (0.0133-0.0243)
Year 2 24 0.0120 (0.0072-0.0168) 0.0308 (0.0236-0.0381)
Year 3 14 0.0088 (0.0042-0.0134) 0.0396 (0.0311-0.0482)
Incidence rate per 100 person-years of exposure
(95% CI)
62 1.46 (1.12-1.87)
Incidence rate per 100 person-years of observation
(95% CI)
82 1.51 (1.20-1.87)
No. of patients at risk is adjusted over time to account for dropouts, deaths, and patients who have already had an event.
CI, Confidence interval.
J AM ACAD DERMATOL
MAY 2013
762 Kimball et alper 100 patient-years of exposure was 5.18 (95% CI,
4.51-5.93) and per 100 patient-years of observation
was 5.58 (95% CI, 4.96-6.27). For serious infectious
events, the Kaplan-Meier estimated 3-year incidence
proportion was 0.04 (95% CI, 0.03-0.05) (Table V).
The incidence rate per 100 patient-years of exposure
was 1.46 (95% CI, 1.12-1.87) and per 100 patient-
years of observation was 1.51 (95% CI, 1.20-1.87). A
total of 459 patients had 1 or more events of medical
interest; events occurring in 5 or more patients are
listed in Table IV. The number of events of NMSC,
lymphoma, and all cancers combined excluding
NMSC (based on patient-years of observation) and
serious infectious events requiring hospitalization
(based on patient-years of exposure, because these
events would be expected to be effects of treatment,
rather than delayed effects, eg, cancer) in this registry
was not higher than that expected for patients with
psoriasis using nonbiologic systemic therapies based
on data from a large administrative health claims
database (Table VI).Efficacy
The mean and median percentages of BSA af-
fected by psoriasis were similar in the prior etaner-
cept and etanercept-naive groups by 6 months
(mean: 7.9% and 8.3%, respectively; median: 4.0%
and 4.0%, respectively). The numbers of patients
included in this 6-month time point were 538 and1538 for prior etanercept and etanercept-naive, re-
spectively, out of 2494 total patients evaluated for
efficacy. In addition, approximately half of patients in
both groups achieved a score of 0 or 1 (clear/almost-
clear status in physician global assessment) in the
physician and patient global assessment by 6months.
For physician global assessment score, 48.6% of
patients achieved a score of 0 or 1 in the prior
etanercept group (n = 539), as did 51.7% in the
etanercept-naive group (n = 1537). For patient global
assessment score, 47.4% of patients achieved a score
of 0 or 1 in the prior etanercept group (n = 529),
versus 50.0% in the etanercept-naive group
(n = 1508). A limitation of the efficacy results is that
not all patients were receiving etanercept throughout
the evaluation period. Atmonth 6, there were 290 pa-
tients who temporarily or permanently discontinued
etanercept despite being evaluated for efficacy, in-
cluding patients who may have discontinued
etanercept, switched to another antipsoriatic treat-
ment, or discontinued all antipsoriatic treatments.
Indeed, some patients who dropped out of the study
were not included in these numbers because of
insufficient available information. The responses
are likely biased upward as a result of missing values.DISCUSSION
These interim analysis results from the first 3 years
of this 5-year etanercept observational safety registry
Table VI. Standardized incidence ratio analysis for events of medical interest using expected rates from
psoriasis population using nonbiologic systemic therapies
Observed
No. of patients Patient-years*
Expected
No. of patientsy SIR (95% CI)
Malignancies, excluding NMSC 39 5537.8 40.1 0.97 (0.69-1.33)
Lymphoma 2 5565.6 2.3 0.88 (0.11-3.17)
NMSCz 48 5489.6 68.3 0.70 (0.52-0.93)
Serious infectious events requiring hospitalization 45 4267.2 86.1 0.52 (0.38-0.70)
CI, Confidence interval; NMSC, nonmelanoma skin cancer; SIR, standardized incidence ratio.
*Based on patient-years of observation data for malignancies (excluding NMSC), lymphoma, and NMSC. For serious infectious events
requiring hospitalization, patient-years of exposure data were used. Nonbiologic systemic therapies include methotrexate and cyclosporine.
yEstimated data from large US administrative health claims database of patients with psoriasis (external comparator) age- and gender-
standardized to OBSERVE-5 study population.
zIncident cases of NMSC only.
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proportions of serious adverse events and serious
infectious events during the follow-up period. The
number of deaths during the 3-year period was 30.
There were 3 deaths judged by the investigator to be
related to etanercept; however, the relationship of
eachof thesedeaths to etanerceptwas confoundedby
pre-existing conditions or time off from etanercept.
The number of serious infections requiring hos-
pitalization (per patient-years of exposure), lympho-
mas, NMSC, and all cancers excluding NMSC (per
patient-years of observation) in this study was not
higher than that expected based on age- and sex-
standardized incidence rates for patients with psori-
asis treated with nonbiologic systemic therapies (eg,
methotrexate, cyclosporine). Although the compar-
ator database analysis provides a context for the
event rates in OBSERVE-5, the case identification
methods differ, and often patients who enroll and
continue participation in prospective observational
studies are healthier than those in the general pop-
ulation.15,16 Therefore, the results should be care-
fully interpreted in this context.
Results from this observational registry paralleled
those from an integrated safety analysis by Pariser
et al17 in 2012 of data from 7 clinical trials of up to
2 years’ duration (total N = 5806). In the analysis of
Pariser et al,17 the rates of serious noninfectious
adverse events were low and generally remained
stable or declined over the long term, with no dose-
related increases in serious infectious events. The
results of our current analysis are also in line with a
recent integrated safety report for etanercept across
approved indications, including psoriasis, which
found generally similar rates of overall serious infec-
tions and malignancies between etanercept and
control groups, along with low overall rates of
opportunistic infections and tuberculosis.18
The use of a large registry in the current analysis
offers several advantages. Data from such a registryrepresent real-world long-term use of etanercept in a
large population of patients with plaque psoriasis. It
has the potential to provide data from a broader
patient population than those enrolled in random-
ized controlled clinical trials,12 although the profiles
of enrolled patients were not dissimilar from the
study populations in terms of basic demographic
data. Limitations inherent to a single-agent registry
include the lack of an internal control group to help
interpret event rates and a lack of power to detect rare
events.12Weused a comparator group thatwas based
on a database analysis. Within this database, we
identified a disease population thatwas likely to have
a similar disease severity as the OBSERVE-5 popula-
tion given that the incidence of some of the outcomes
is known to be higher in those with more severe
psoriasis. Although patientswith psoriasis prescribed
other anti-TNF therapies should have the most com-
parable disease severity, that group might not be the
most appropriate comparator group given that there
might be similar safety issues for the entire class.
Interpretation of registry data is also constrained by
patients lost to follow-up, in part because of the long
duration of the study and the fact that study drug was
not provided to patients. The registry also does not
provide data on phenotypic and genetic components
of psoriasis and their relationship to treatment re-
sponse, adverse events, and disease severity. Further,
there is potential observation bias by investigators
who assessed patients more than twice yearly, and
for recall bias by patients when reporting adverse
events. The retrospective nature of event capture
may have led to recall bias. Finally, the efficacy
estimates do not account for the patients who
discontinue etanercept or use other therapeutic
agents and may thus overestimate efficacy.
CONCLUSIONS
In summary, this analysis found that no new or
unexpected safety concerns were observed in the
J AM ACAD DERMATOL
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postmarketing registry. Data will continue to be
collected and final results will be reported at
study end.
Dr Kenneth Rothman is thanked for his review and
comments.
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